Multicenter Study on the Safety of Pulsed Field Ablation in Over 40,000 Patients: MANIFEST-US

Authors

Mohit K Turagam
Arash Aryana
John D. Day, HCA HealthcareFollow
Srinivas R Dukkipati
Troy Hounshell
Devi Nair
Andrea Natale
Stanislav Weiner
Jim W Cheung
Larry Chinitz
Frank Cuoco, HCA HealthcareFollow
Marcos Daccarett
Sanjay Dandamudi
Alok Gambhir
Maheer Gandhavadi
Jamie Kim
Mark D Metzl
Bradley Mikaelian
Darren Peress
Jorge E Romero
Javier Sanchez
David A Sandler
Naushad A Shaik
Michael Shehata
Sultan M Siddique
Abhinav Singh, HCA HealthcareFollow
Matthew J Singleton
Sri Sundaram
Yoel Vivas
Jonathan W Waks
Kenneth H Yamamura
Matthew Zipse
Joon Ahn
Obadah Al Chekakie
Mahmoud Ali
Nameer Ascandar, HCA HealthcareFollow
Sandeep Bansal
Andrew D Beaser
Jaskanwal Bisla
Scott Brancato
David J Callans
Peter Chang-Sing
Rashaad Chothia
Joseph Dell'Orfano
David B DeLurgio
Shephal K Doshi
Lynn Erickson
Sandeep Gautam
Venkateshwar Gottipaty
Sandeep Goyal
Sanjaya Gupta
Jamal Hajjari
John D Harding
Jessica Hennessey
Huy V. Ho, HCA HealthcareFollow
Ivan Ho
Jonathan C Hsu
Henry D Huang
Matthew Hutchinson
Rachel Kaplan
Sreekanth Karanam
Nayanjyoti Kaushik
David N Kenigsberg
Arfaat Khan
Bradley Knight
Jordan Leyton-Mange
Bernard Lim
Theodore J Maglione
Bobby Malik, HCA HealthcareFollow
Matthew McKillop
Donald Mehlhorn
Davendra Mehta
Suneet Mittal
Kent R Nilsson
Samuel Omotoye
Hakan Oral
Ragesh Panikkath
Apoor Patel
Christian Perzanowski
Anil Rajendra
Mansour Razminia
Samir Saba
Jose M Sanchez
Danish Iltaf Satti
Navinder Sawhney
Dinesh Sharma
Robert Sheppard, HCA HealthcareFollow
Madhurmeet Singh
Jasbir Sra
James E Stone
Ravi Sureddi
Matthew Taylor, HCA HealthcareFollow
Todd L Teigeler
Venkat Tholakanahalli
Amar Trivedi
Kevin M Trulock
Ganesh Venkataraman
Daniel Weitz
Brian D Williamson
Stephen L Winters
Jennifer M Wright
Richard Wu
David Yoo
Anthony Aizer
Daniel Dan Alyesh
Luciano Amado
Ryan Borne
Nagib Chalfoun
David Chang
Megan Davis
Ashkan Ehdaie
Paul Z Gerczuk
Jefferson H Lee
Gregory Michaud
Hiroshi Miyama
Sanghamitra Mohanty
Luis Mora
George Mounir
Nischala Nannapaneni
Jose Nazari
Graham Peigh
William H Sauer
Darren Sidney
Vivek Varughese
Wendy Tzou
Ugur Gurol
Vivek Y Reddy

Division

West Florida

Hospital

Regional Medical Center Bayonet Point

Document Type

Manuscript

Publication Date

1-20-2026

Keywords

Humans, Male, Female, Atrial Fibrillation, Middle Aged, Aged, Retrospective Studies, Adult, Catheter Ablation, Aged, 80 and over, United States, Adolescent, Young Adult, Postoperative Complications

Disciplines

Cardiology | Cardiovascular Diseases | Internal Medicine | Medicine and Health Sciences | Surgical Procedures, Operative

Abstract

BACKGROUND: Pulsed field ablation (PFA) is emerging as the preferred energy source for atrial fibrillation ablation, largely because of its promising safety profile, including lower risks of esophageal injury, pulmonary vein stenosis, and phrenic nerve injury. However, rare complications may only emerge after treating many thousands of patients.

OBJECTIVES: This study sought to determine the real-world utilization and safety profile of the pentaspline PFA catheter in the United States.

METHODS: In this retrospective analysis, invitations were sent to U.S. centers performing PFA with the pentaspline catheter. Centers submitted data on patient demographics, procedural details, and adverse events (AEs). The main outcomes included the incidence of major and minor procedure-related AEs.

RESULTS: Of the 435 centers contacted, 102 participated, averaging 5.1 operators per center (range 1-16 operators per center). Each center treated a median of 412 patients (range 26-1,961 patients), totaling 41,968 patients between February 2024 and July 2025. The median patient age was 68 years (range 17-99 years), and 56% were male. Most patients underwent first-time ablation (73%), primarily for paroxysmal (54%) or persistent atrial fibrillation (37%). Pulmonary vein isolation was performed in 93% of patients, with extravenous lesions on the posterior wall (57%), cavotricuspid isthmus (31%), or mitral isthmus (14%). Major AEs occurred in only 0.63% of patients, including cardiac tamponade (0.16%), vascular injury requiring intervention (0.18%), and stroke (0.10%). Importantly, no cases of esophageal fistula, persistent phrenic nerve paralysis, or pulmonary vein stenosis occurred. Mortality at 30 days was rare (0.04%), but there was a potential signal for rare (0.019%) unexplained sudden death/cardiac arrest. Rare AEs included coronary spasm (0.10%) and acute renal failure requiring dialysis (0.02%). Minor complications were reported in 2.05%, mainly vascular issues (0.96%), pericarditis (0.52%), and self-limited esophageal dysmotility (0.04%).

CONCLUSIONS: In a real-world setting of unselected U.S. patients, PFA demonstrated a safety profile consistent with preferentiality to functional myocardial tissue ablation, without evidence of esophageal fistula or pulmonary vein stenosis. The major complication rate was ∼0.6%-mostly vascular AEs and pericardial tamponade. Stroke (∼1 in 1,000) and death (∼1 in 2,000) were rare. These data indicate that the initial implementation of pentaspline PFA has been overall safe.

Publisher or Conference

Journal of the American College of Cardiology

Share

COinS